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Recent advances in our knowledge of the biochem- 
istry, pharmacology, and cell biology of ligand-in- 
duced, stimulated turnover of inositol lipids in such 
diverse tissues as insect salivary glands, platelets, lym- 
phocytes, and a number of exocrine glands have 
greatly altered our understanding of intracellular 
events leading to secretion, contraction, chemotaxis, 
and other cellular responses. Much of what has been 
learned regarding ligand-stimulated turnover of inosi- 
to1 lipids has come from nonneural systems, so that 
the presumption that signal transduction via this 
mechanism mediates significant steps in neural func- 
tion must still be considered inferential. This reserva- 
tion has been a major theme of a recent comprehen- 
sive review (Hawthorne, 1986). Nevertheless, that the 
brain contains large amounts of the substrates and en- 
zymes of inositol lipid turnover and its associated sec- 
ond messenger systems and, further, that it is enriched 
with receptors that are linked to stimulated inositol 
lipid turnover argue strongly that the phosphoinosi- 
tides indeed play an important role in brain function. 
There exist several general reviews on stimulated ino- 
sitol lipid turnover (Bemidge, 1984; Bemdge and Ir- 
vine, 1984; Nishizuka, 1984, 1986; Hokin, 1985; Ab- 
del-Latif, 1986; Downes, 1986; Williamson, 1986), in- 
cluding several that emphasize the nervous system 
(Downes, 1982, 1983; Fisher and Agranoff, 1986; 
Hawthorne, 1986; Nahorski et al., 1986). The present 
contribution emphasizes developments of neuro- 
chemical relevance since a review on the subject in 
this journal 8 years ago (Hawthorne and Pickard, 
1979). 
CHEMISTRY AND ENZYMOLOGY 
OF INOSITOL LIPIDS AND 
INOSITOL PHOSPHATES 
The inositol lipids 
Phosphatidylinositol (PI), depicted in Fig. lA, is a 
glycerophospholipid in which the sn- 1 and sn-2 posi- 
tions of glycerol are esterified to fatty acids, whereas 
the sn-3 position is phosphodiesterified to the 1)- 1 po- 
sition of myo-inositol. myo-Inositol is one of nine pos- 
sible isomers of hexahydroxycyclohexane, which, in 
its preferred chair conformation, has one axial and 
five equatorial hydroxyl groups. The molecule can be 
likened to a turtle (Fig. 1B) in which the four legs and 
tail are the five equatorial hydroxyls, numbered coun- 
terclockwise from above, starting with the right fore- 
leg as position D- 1 (Fig. 1 C). The turtle’s head is thus 
the axial hydroxyl at position D-2. The phosplhatidyl 
group in all of the phosphoinositides is linked to D- 1 
(the right foreleg). 
PI is synthesized in brain from a liponucleoiide in- 
termediate, cytidine diphosphodiacylglycerol (CDP- 
DG) (Agranoff et al., 1958), and inositol in the pres- 
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FIG. 1. The chemical structure of the inositol lipids. A PI and the 
polyphosphoinositides. In the D numbering system, the 2 position 
is axial, and the phosphatidyl group is phosphodiesterified to the 
vicinal hydroxyl in the D-1 position. In PIP, there is an additional 
phosphate monoesterified in the D-4 position, and in PIP2, a third 
phosphate is present on the 0-5 position. The site of cleavage via 
phosphoinositide phosphodiesterase is shown by the arrow. myo- 
lnositd may be visualized as a turtle (B) in which the 2 position is 
the head and the five equatorial hydroxyls constitute the four legs 
and tail. in the inositol lipids, the phosphatidyl group is always at 
the right foreleg (D-1). C: A convenient representation of myo- 
inositol. The open triangle at the D-2 position represents the axial 
hydroxyl (the turtle’s head) projecting out of the plane of the paper 
toward the reader (from Agranoff, 1987). 
ence of a transferase (Benjamins and Agranoff, 1969) 
and can then be phosphorylated via PI kinase and 
ATP to form phosphatidylinositol4-phosphate (PIP) 
(Colodzin and Kennedy, 1965; Kai et al., 1966). This 
product may be further phosphorylated via PIP kinase 
and ATP to form phosphatidylinositol 4,5-bisphos- 
phate (PIP2) (Kai et al., 1968). It had been shown by 
Hokin and Hokin (1 955), in studies in which intact 
cell preparations were incubated in the presence of 
muscarinic ligands, that the labeling of two quantita- 
tively minor lipids, phosphatidate (PA) and PI, was 
enhanced. It was suggested that the ligand stimulated 
the phosphodiesteratic cleavage of PI (Hokin and 
Hokin, 1964) to yield diacylglycerol (DG), which 
could then be converted to PA by DG kinase (Hokin 
and Hokin, 1959) and, thence, via de novo synthesis 
(Petzold and Agranoff, 1965, 1967; Carter and Ken- 
nedy, 1966) to PI. Phosphodiesterolysis of PI via a 
phospholipase C-type cleavage (Dawson, 1959; Kemp 
et al., 1959) was then proposed to complete a cycle 
(Fig. 2a). It has become increasingly clear in the last 
few years that the initial ligand-stimulated step is the 
stimulated breakdown of PIP2 rather than that of PI 
(Fig. 2b), with the concomitant formation of DG and 
inositol 1,4,5-trisphosphate ( 1,4,5-IP3) (Akhtar and 
Abdel-Latif, 1980; Agranoff et al., 1983; Berridge et 
al., 1983). The two products of this phosphodiestera- 
tic cleavage are now known to have separate second 
messenger properties: DG stimulates protein kinase C 
(PK-C), a Ca2+-activated protein kinase (Nishizuka, 
1984), whereas IP3 mobilizes Ca2+ from intracellular 
stores (Berridge and Irvine, 1984). The brain is partic- 
ularly enriched in PK-C (Hirasawa and Nishizuka, 
1985), and several brain-specific proteins have been 
shown to be selectively phosphorylated via this kinase 
(Nishizuka, 1986). In platelet membranes, the three 
inositol phospholipids, PI, PIP, and PIP2, all appear 
to be cleaved by a common phosphodiesterase in the 
presence of Ca2+ (Wilson et al., 1984), although when 
Ca” is reduced by EGTA chelation, only PIP and 
PIP2 are hydrolyzed. In brain membranes, Ca” is re- 
quired for phospholipase C cleavage of PIP and PIP, 
(Van Rooijen et al., 1983). Although there is evidence 
that the initial cleavage stimulated by ligand is at the 
level of polyphosphoinositides, at later times the resul- 
tant elevated intracellular Ca” levels could then lead 
to further phosphodiesteratic breakdown of PI (Wil- 
son et al., 198%). Because the brain, like other tissues, 
contains much more PI than PIP or PIP2, PI is poten- 
tially a more plentiful source of DG for activation of 
cDTG PI 
FIG. 2. Stimulated turnover of inositol lipids in response to ligand 
receptor activation. An earlier view of the cycle considered PI 
breakdown to DG to be stimulated (a). Evidence in the last few 
years indicates that the stimulated breakdown occurs at the level 
of PIPp (b) (from Fisher and Agranoff, 1986). 
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PK-C. It should be noted that lipid metabolism out- 
side the phosphoinositide cycle can both produce and 
consume DG (see Daniel et al., 1986; Snider et al., 
1987). 
The Ca2’ sensitivity of stimulated phosphoinositide 
turnover in the CNS represents a major characteristic 
of neural tissues. Omission of Ca2+ from the incuba- 
tion medium can attenuate, and inclusion of Ca2+ 
chelators can abolish, stimulated inositol lipid turn- 
over in brain (Griffin et al., 1979; Fisher and Agranoff, 
1980, 1981; Gonzales and Crews, 1984; Pearce et al., 
1985). Moreover, in some circumstances, addition of 
the divalent cationophore A23187 can mimic the 
stimulatory effect of the natural ligand on phospho- 
inositide turnover (Griffin and Hawthorne, 1978; 
Fisher and Agranoff, 198 1; Kendall and Nahorski, 
1984). Depolarizing concentrations of Kf can elicit 
an increased inositol lipid breakdown in sympathetic 
ganglia and brain slices (Bone and Michell, 1985; 
Kendall and Nahorski, 19854, and the Ca2+ channel 
activator BAY-K-8644 can mimic K+ depolarization 
(Kendall and Nahorski, 198%). Although some of 
these effects may be indirect, e.g., via release of a neu- 
ropeptide, as suggested by Bone and Michell(1983, 
a direct effect of elevated intracellular [Ca”] on the 
inositide phosphodiesterase seems possible. Whether 
this phosphodiesterase is actually regulated by physio- 
logically relevant changes in intracellular [Ca2’] 
seems less certain. Nevertheless, this possibility 
should not be excluded, because in both permeabi- 
lized bovine chromaffin cells and GH3 pituitary cells, 
PIP2 phosphodiesterase activity is increased in the 
presence of Ca2+ concentrations that are well within 
physiological limits (Martinet al., 1986; Eberhard and 
Holz, 1987). 
That it took so many years to recognize that stimu- 
lated phospholipid breakdown occurs at the level of 
PIP2 rather than PI (Fig. 2) can be attributed to several 
technical factors. For example, conventional lipid ex- 
traction does not extract PIP or PIP,. But even with 
the requisite acidified lipid extraction procedure, tech- 
niques that permit PIP and PIP2 to migrate and sepa- 
rate on TLC plates were developed only in the past 
few years (Jolles et al., 1981; for review, see Hajra et 
al., 1987). Furthermore, the 4’ and 5’ positions of the 
polyphosphoinositides are rapidly labeled with 32Pi 
via the phosphoinositide kinase and phosphatases, 
and these steps are insensitive to ligand stimulation. 
Label in these two positions tends to equilibrate 
quickly with that in the y phosphate of ATP and, thus, 
to reflect more the amounts of PIP and PIP2 in a prep- 
aration than their stimulated labeling. Because of this, 
possible stimulated labeling in the D- 1 phosphodies- 
ter position is obscured. 
In all three of the inositol lipids, there is an enrich- 
ment in stearate at sn-1 and of arachidonate at sn-2. 
One might then expect that stearoyl arachidonoyl DG 
would be selectively efficacious in activating PK-C. 
This has not yet proven to be the case. In fact, there is 
very little demonstrated fatty acid specificity in DG 
effects on PK-C (Mori et al., 1982). The synthetic DG 
1-oleoyl-2-acetyl-sn-glycerol has been particularly 
useful experimentally because of its high solubility. 
Phorbol esters have proven to be excellent tools for 
studying activation of PK-C, because they can be 
taken up by cells and bind to the DG site. Increased 
intracellular Ca2’ levels can activate phospholipase 
A2, so that phosphoinositide-related activation may 
release free fatty acids. Because arachidonate is a pre- 
cursor of the prostanoids, there may be a link between 
stimulated inositide turnover and stimulation of pro- 
stanoid synthesis. It should be pointed out, however, 
that if the labeling cycle is to be preserved, DG must 
survive. This appears to be the case for nerve ending 
preparations, because following carbamoylcholine 
stimulation, 74-85% of 32P-labeled PA and PI pro- 
duced could be accounted for by the tetraenoic spe- 
cies, as detected by argentation TLC (Van Rooijen et 
al., 1985). Nevertheless, deacylation-reacylation reac- 
tions could exchange arachidonate for other fatty 
acids in DG or in any one of a number of intermedi- 
ates of the cycle depicted in Fig. 2b. 
Much work on stimulated inositol lipid turnover in 
the nervous system has used the muscarinic receptor 
as its model. As described below, it has been shown in 
hippocampus that the stimulated turnover is related 
to a postsynaptic neuronal site. Figure 3 attempts to 
integrate the presently known reactions in stimulated 
phosphoinositide turnover within the typical concep- 
tualization of a muscarinic synapse. 
The inositol phosphates 
The brain contains several inositol phosphates 
(Agranoff, 1978), as well as high levels of free myo- 
inositol relative to other tissues (Sherman et al., 1968). 
The inositol phosphates D-myo-inositol 1 -phosphate 
(D- 1-IPl), D-myo-inositol 1 ,4-bisphosphate (D- 1,4- 
IP2), and ~-1,4,5-IP~ (see Fig. 4) are the products of 
phosphodiesteratic cleavage of PI, PIP, and PIP2, re- 
spectively. The three inositol phosphates may also ex- 
ist as 1,2 cyclic derivatives, in which a five-membered 
phosphodiesteratic ring is formed between the D- 1 
equatorial and the D-2 axial positions. D- 1,2 (cyclic) 
myo-inositol phosphate [(cl ,2)-IPl] is the best charac- 
terized of the cyclic inositol phosphates (Pizer and 
Ballou, 1959). It is produced in roughly equal 
amounts with D- l-IPI on phosphodiesteratic cleavage 
of PI (Dawson et al., 197 1). It is tempting to speculate 
that the cyclic derivatives are initial products of the 
phosphoinositide phosphodiesterase and are eventu- 
ally cleaved at the 2 position by a cyclic IP phosphodi- 
esterase. Cyclic IP3 may be degraded to cIP2, thence 
to cIPl, and finally to IPl . The argument is given sup- 
port by the recent isolation from placenta of a phos- 
phodiesterase that acts on cIPl but that is not active 
against cyclic derivatives of IP2 or IP3 (Ross and Maj- 
erus, 1986). The brain also contains D-~-IP, (the same 
compound as L- 1-IPJ, derived from the reductive cy- 
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FIG. 3. Diagram of ACh release, muscarinic recep- 
tor activation, and second messenger actions in the 
CNS. ACh released presynaptically (1) is either hy- 
drolyzed by acetylcholinesterase (2) followed by up- 
take of choline (Ch) (3) or, alternatively, interacts 
with the muscarinic receptor on the postsynaptic 
cell surface (4). The activated receptor-ligand com- 
plex, possibly acting through a G-protein (5), leads 
to phosphodiesteratic cleavage (6) of PIPp. A prod- 
uct, DG, activates PK-C (7), which then catalyzes 
protein (X) phosphorylation in the presence of Ca“, 
leading to physiological cell responses by as yet un- 
established mechanisms. The other product of PIPp 
cleavage is 1,4,5-&, and, very likely, its 1,2 cyclic 
derivative (see text). 1,4,5-IP3 binds to the endo- 
plasmic reticulum (ER) resulting in increased cyto- 
solic Cap+ (8), thus activating Ca2’-dependent pro- 
tein kinases that phosphorylate other classes of 
protein substrates (Y). The action of 1,4,5-IP3 can 
be terminated by a membrane-bound 5’-phospho- 
hydrolase (9), yielding 1 ,4-IP2, which has no Ca2+- 
mobilizing action; 1 ,4,5-IP3 may alternatively be 
phosphorylated to IP4 via a 3’-kinase (10) present in 
brain cytosol. The fate of IP4 is not known, but it is 
tempting to speculate that there exist alternatives: 
The 5’-phosphohydrolase is expected to degrade 
IP4 to the known inactive isomer 1,3,4-IP3 ( l l ) ,  
whereas a hypothetical 3‘-phosphohydrolase (1 2) 
would reconvert the IP, to 1 ,4,5-IP3. DG is inacti- 
vated by its conversion, via DG kinase (13), to PA, 
thus initiating recycling to PIP, via CDP-DG, PI, and 
PIP. PIP kinase (14) and PIPp phosphatase (15) to- 
gether constitute an enchange system that rapidly 
equilibrates the 5-phosphate of PIP2 with the y 
phosphate of ATP. Also shown is the muscarinic re- 
ceptor that is negatively coupled to adenylate cy- 
clase (16). CAMP, cyclic AMP; R, receptor. 
c D p c l < +  
clization of glucose 6-phosphate (Eisenberg, 1967). 
The brain, like testis, may be a net producer of inosi- 
tol. The same phosphatase cleaves both D- 1- and D- 
3-IP1 and is inhibited by Li+ (Hallcher and Sherman, 
1980). This observation was used to advantage by Ber- 
ridge et al. (1982) in devising an assay for stimulated 
inositol lipid turnover with [3H]inositol. The presence 
of Li+ permits the accumulation of labeled IP, , which 
otherwise would be degraded by the phosphatase. Of 
the various inositol phosphates, 1 ,4,5-IP3 has been of 
most interest because of its demonstrated ability to 
mobilize Ca” from intracellular stores in the endo- 
plasmic reticulum (Streb et al., 1983; Burgess et al., 
1984; Thomas et al., 1984; Prentki et al., 1984), prob- 
ably through its interaction with specific receptor sites 
(Baukul et al., 1985; Spat et al., 1986a,b). The effect 
of IP3 on endoplasmic reticulum may be mediated by 
a guanine nucleotide regulatory mechanism (Daw- 
son, 1985; Gill et al., 1986). Because the highly 
charged molecule cannot readily enter cells, demon- 
stration of its effects has required permeabilization of 
cells by various means or, in the case of large cells such 
as oocytes (Oron et al., 1985), direct injection of IP3. 
Irvine et al. ( 1984) found the presence of a form of IP3 
that is inactive in Ca2+ mobilization and. in a series of 
ingenious experiments, established its structure as the 
1,3,4 isomer. It now appears that the source of the 
1,3,4 isomer is I ,4,5-IP3: 1,4,5-IP3 is phosphorylated 
by a specific kinase present in brain extracts to form 
D-myo-inositol 1,3,4,5-tetrakisphosphate (1,3,4,5- 
IP4) (Batty et al., 1985; Irvine et al., 1986). It can then 
be selectively dephosphorylated by the specific 5’- 
phosphohydrolase in brain (Erneaux et al., 1986) to 
yield the 1,3,4 isomer. What, then, is the significance 
of these reactions? At present, it appears that IP4 does 
not mobilize Ca2+ from intracellular stores, although 
it has been postulated that it may actually gate Ca2+ 
across the plasma membrane (Hansen et al., 1986). 
One may speculate that, in addition to the known 5’- 
phosphohydrolase, thought to be the “off’ enzyme of 
the Ca2+ mobilization signal of 1,4,5-IP3 (Connolly et 
al., 1985), there may also be a 3’-phosphohydrolase. If 
this proves to be the case, then IP4 might be preferen- 
tially converted back to the 1,4,5 isomer via the action 
of the putative 3’-phosphohydrolase, rather than to 
the inactive isomer 1 ,3,4-IP3, even though this does 
not appear to be the case in the parotid gland (Haw- 
kins et al., 1986). These possibilities are shown in Fig. 
5, which also entertains the alternative that these vari- 
ous steps are occurring with the 1,2 cyclic derivatives 
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FIG. 4. Higher phosphates of D-myo-inositol. Structures (a), (b), 
and (c) depict IP1, IP2, and IP3, respectively. These are the cleav- 
age products of PI, PIP, and PIPz. Structure (d) is IP4, produced 
by phosphorylation at the D-3 position via IP3 kinase. Structures 
(e), (f), (g), and (h) represent 1,2 cyclic derivatives of compounds 
(a), (b), (c), and (d), respectively. (cl ,2)-IP1 is the best character- 
ized, and there is increasing evidence for the occurrence in tissues 
of (cl ,2)4-IP2 and (cl ,2)4,5-lP3. The latter compound was first 
proposed many years ago (Agranoff and Seguin. 1974). The exis- 
tence of (cl ,2)3,4,5-lP4 is presently speculated. Structure (i) is D- 
myo-inositol 3-phosphate, also known as L-l-IP, . This ester is 
formed from cyclization of glucose 6-phosphate. Structure (i) is D- 
4,5-IP2. Structure (k) is 1,3,4-IP3, an inactive isomer of IP3 (see 
text). Structure (I) is D-myo-inositol 1,3,4,5,6-pentakisphosphate. 
This isomer is present in avian erythrocytes in relatively high 
amounts, but may possibly be present in other tissues. 
of IP3 and IP4 (Connolly et al., 1986). It is of interest, 
in this regard, that when (c1,2)4,5-IP3 is injected into 
the photoreceptor cells of the horseshoe crab, Limu- 
lus, a membrane conductance change is seen similar 
to that induced by light, with a potency five times that 
seen with the noncyclic derivative, 1 ,4,5-IP3 (Wilson 
et al., 1985~). 
One may wonder why it is IP3, rather than IP2 or 
IP, , that is recognized by the cell as the signal for Caz+ 
mobilization. In this regard, it has been hypothesized 
(Holmsen et al., 1985) that the relative amounts of 
membrane PI, PIP, and PIP2 reflect the energy charge 
of the cell, such that PIPz content is reduced at low 
energy levels. Thus, we may speculate further that a 
cell is protected from increasing its intracellular Caz+ 
content when its ATP content is low: When mem- 
brane PIPz content is reduced, IP3 production is also 
reduced. This safety device would then protect the cell 
from self-destruction, because increasing intracellular 
Ca" levels under conditions when this cation cannot 
be quickly removed (i.e., low ATP levels) would lead 
to activation of Caz+-mediated proteases, of phospho- 
lipase Az, etc., which, if sustained, would result in ir- 
reparable cellular damage. 
INTRACELLULAR MESSENGER 
GENERATION AND BIOCHEMICAL 
SEQUELAE 
Calcium signaling 
It is perhaps a reflection of the daunting complexity 
of the CNS that direct evidence linking PIPz break- 
down and the generation of Ca2+ signals has, thus far, 
been restricted to simple neurotumor cells, such as the 
pheochromocytoma PC- 12, neuroblastoma N1 E- 
l 15, neuroblastoma-glioma hybrid NG- 108- 15, and 
astrocytoma 132 IN1 cells. In each of these cell types, 
addition of agonists known to promote the break- 
down of inositol lipids also elicits a demonstrable in- 
crease in intracellular [Ca"], even though the inten- 
sity and duration of the Ca2+ signal differs considera- 
bly, depending on cell type and ligand in question 
(Masterset al., 1984; Yano et al., 1984; Orellana et al., 
1985; Vicentini et al., 1985; Snider et al., 1986). The 
possible linkage of PIP2 breakdown and Ca2+ signals 
has also been examined in bovine chromaffin cells. 
Activation of muscarinic receptors in these cells re- 
sults in an increased turnover of inositol lipids (Fisher 
et al., 1981b; Mohd. Adnan and Hawthorne, 1981), 
but only a modest increase in intracellular [Ca2+], 
from 100 to 150 nM (Kao and Schneider, 1985), 
which is apparently insufficient to elicit an increase in 
catecholamine release (Fisher et al., 198 1 b; Cheek and 
Burgoyne, 1985). Because IP3 addition to permeabi- 
lized chromaffin cells results in the mobilization of in- 
tracellular Ca2+, the failure of muscarinic acetylcho- 
( C  1,2)3,4-IP3 I ,3,4 - IP3 
I t t 
( C  1,2) 3,4,5-IPq I ,  3,4,5-IP4 
t t 
I 






( c  1,2) -IP1 - k I P I  
1 
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FIG. 5. Metabolic interconversion of inositol phosphates. IP3 pro- 
duced by phosphodiesteratic cleavage of PIPp can be converted 
to IP4 via IP3 kinase. By action of a 5'-phosphohydrolase, IP4 can 
be converted to the inactive isomer 1 .3,4-IP3. It is also possible 
that the sole initial product of PIPz cleavage is clP3 and that the 
kinase and phosphatases act on the 1,2 cyclic derivatives, as indi- 
cated. 
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line (ACh) receptor (mAChR) activation to initiate 
catecholamine release clearly does not result from the 
absence of IP3 “receptors” on intracellular mem- 
branes (Stoehr et al., 1986). The situation is further 
complicated by the fact that distinct species differ- 
ences exist for the biochemical and physiological con- 
sequences of mAChR activation in chromaffin cells. 
Thus, in the guinea pig, mAChR activation results in 
catecholamine release (Role and Perlman, 1983), as 
well as an enhanced turnover of inositol lipids (Fi- 
gueiredo et al., 1986). One implication from this find- 
ing is that in those species, e.g., rat or guinea pig, in 
which muscarinic receptor activation results in cate- 
cholamine release, more IP3 is produced or less is de- 
graded than in the bovine cell. However, because ad- 
dition of phorbol esters such as 4P-phorbol 12-myris- 
tate 13-acetate (PMA) to guinea pig cells can mimic 
the effect of muscarinic stimulation on catecholamine 
release both temporally and quantitatively (Fi- 
gueiredo et al., 1986), the further possibility must be 
considered that activation of PK-C is of primary rele- 
vance for initiation of exocytotic events. 
Production of DG: role in protein phosphorylation 
It is now well established that DG released from the 
breakdown of PIP2 may serve to activate PK-C, and 
that as a result, its affinity for Ca2+ is lowered, such 
that in the presence of phosphatidylserine, concentra- 
tions of Ca2+ as low as 0.1 pM fully activate the en- 
zyme (Nishizuka, 1984; Hirasawa and Nishizuka, 
1985). What is much less clear is the identity of spe- 
cific substrate proteins for PK-c. Gispen and col- 
leagues have proposed that a membrane protein desig- 
nated BSO may be one such substrate (Van Dongen et 
al., 1985) and that the phosphorylated form inhibits 
PIP kinase. Addition of corticotropin ( 1 -24)tetraco- 
sapeptide (ACTH) inhibits BS0 phosphorylation, with 
the net effect that addition of the neuropeptide leads 
to an increase in PIP2 synthesis. This result suggests 
that DG, acting through PK-C, is a regulator of PIP2 
steady-state concentrations in neural membranes. Al- 
though in this case DG ultimately reduces PIP2 con- 
centrations, it may also inhibit receptor-mediated 
breakdown of PIP2. Labarca et al. (1984) demon- 
strated that addition of PMA at nanomolar concen- 
trations results in an inhibition of carbachol-induced 
release of inositol phosphates from hippocampal 
slices, whereas the basal turnover of the lipid pool is 
unaffected. A similar result was obtained by Kanba et 
al. (1986) with NlE-115 cells. In cultured astrocy- 
toma cells, phorbol esters block both the carbamoyl- 
choline-stimulated breakdown of inositol lipids and 
the resulting Ca2+ signal (Orellana et al., 1985). The 
mechanism of this inhibition remains unknown for 
most cells, but in the DDTl MF-2 smooth muscle cell 
line, PMA addition results in phosphorylation of the 
Q! ,-adrenergic receptor itself (Leeb-Lundberg et al., 
1985). That phorbol esters are capable of modulating 
neuronal physiology is supported by the recent dem- 
onstration that addition of PMA can alter ionic con- 
ductance in hippocampal pyramidal cells (Baraban et 
al., 1985) and in Aplysia bag cells (De Riemer et al., 
1985). However, application of phorbol esters to hip- 
pocampal pyramidal cells can mimic some, but not 
all, of the electrophysiological responses associated 
with activation by a receptor agonist (Malenka et al., 
1986). 
Evidence that both DG and IP, may play a pivotal 
role in neuronal signaling was recently obtained by 
Higashida and Brown (1986) using the NG108-15 
neuroblastoma-glioma hybrid cell line. In these cells, 
addition of bradykinin results in both a hyperpolar- 
ization and a depolarization of the membrane. The 
hyperpolarization response is mimicked by intracellu- 
lar injection of either Ca2+ or IP, , whereas depolariza- 
tion can be elicited by addition of phorbol esters or 
1 -oleoyl-2-acetylglycerol. These results suggest that in 
NG 108- 15 cells, the initial breakdown of PIP2 results 
in message formation that first inhibits and then accel- 
erates neuronal discharge, and that in this way, neuro- 
nal signaling is modified. 
PHARMACOLOGICAL CHARACTERISTICS 
The availability of novel selective ligands together 
with the development of more specific assay methods 
for phosphoinositide turnover has resulted in signifi- 
cant advances in our understanding of receptor cou- 
pling to inositol lipid turnover. The number of recep- 
tors implicated in inositol lipid turnover in the CNS 
continues to grow, and in several instances, there is 
evidence for the involvement of a specific receptor 
subtype. Furthermore, the relationship between the 
binding of ligands to the receptor and the ensuing acti- 
vation of phospholipase C has begun to unfold. At 
least 1 7 pharmacologically distinct receptor types 
have been claimed to be coupled to inositol lipid turn- 
over (Table l), but the amount of evidence supporting 
the involvement of each receptor in question vanes 
considerably. They have been subdivided into two 
groups on the basis of the strength of available sup- 
portive evidence. In addition, a third group of recep- 
tors is identified for which there is good evidence that 
they are not linked to activation of phosphoinositide 
phosphodiesterase. 
A. Receptors established to be coupled to 
phosphoinositide turnover 
Muscarinic cholinergic. The initial observations 
that activation of mAChRs in brain slices resulted in 
an increase in phosphoinositide turnover has since 
been amply confirmed in a variety of neural prepara- 
tions, including nerve ending preparations, brain 
minces, and primary cultures of neurons and glia, as 
well as transformed cells of neural origin, such as neu- 
roblastoma and astrocytoma (for review, see Fisher 
and Agranoff, 1985). Within the CNS, there exists a 
strong correlation between the density of mAChRs, 
as determined by radioligand binding techniques, and 
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TABLE 1. Pharmacological proJile of receptor-activated phosphoinositide lurnover in CNS and neural-related tissues 
~ ~~~ 
Reference Receptor Subtype(s) Tissue 
Adrenergic 
A. Receptors demonstrated to be coupled to phosphoinositide turnover 
Muscdrinic cholinergic M I  and M2 Brain slices Bemdge et al. (1982), Brown et al. (1984), 
Fisher et al. (1984), Gonzales and Crews 
(1984), Fisher and Bartus (1985), Gil and 
Wolfe (1989, Jacobson et al. (1989, 
Lazareno et al. (1983, Eva and Costa 
(1986),Heacocketal. (1987) 
Primary neuronal cultures 
Primary glial cultures 
Synaptoneurosomes 
Astrocytoma I32 IN 1 
Neuroblastoma N 1 E- 1 I5 
Neuroblastoma-glioma NG 108- 15 
Superior cervical ganglion 
Pheochromocytoma Vicentini et al. (1985) 
Adrenal medulla 
Gonzales and Crews (1985) 
Pearce et al. (1985) 
Gusovsky et al. (1 986) 
Masters et al. (1984), Evans et al. ( I  985) 
Cohen et al. (1983), Kanba et al. ( 1  986) 
Siman and Klein ( I  98 I )  
Bone et al. (1984), Honvitz et al. (1984) 
Fisher et al. (198 1 b), Mohd. Adnan and 
Hawthorne (1  98 I) ,  Ohsako and Deguchi 
(1983), Eberhard and Holz (1987) 
Young et al. (1979), Hauser and Parks ( I  983) 
Akiyama et al. (1986) 
Berridge et al. (1982), Schoepp et al. (1984), 
Johnson and Minneman (1985), Kendall 
et al. (1989, Minneman and Johnson 
(1984), Fowler et al. (1  986), Kemp and 
Downes ( 1986) 
Pituitary 
Pituitary tumor cells 
Brain slices 
Synaptoneurosomes Gusovsky et al. ( I  986) 
Histaminergic H I  Brain slices Daum et al. (1983, 1984), Carswell and 
Young ( 1986), Claro et al. ( I  986), 
Donaldson and Hill ( I  986) 
Cohen et al. (l983), Snider et al. (1984) 
Nakahata et al. ( I  986) 
Neuroblastoma N I E- I I5 
Astrocytoma 132 1 N I 
Serotonergic 5-HT2 and 5-HTl, Brain slices (cerebral cortex) Conn and Sanders-Bush (1984, 1985, 1986). 
Choroid plexus 
Glutamatergic ? Brain slices Nicoletti et al. (1985, 1986a,b) 
Primary cultures 
Kendall and Nahorski (1985b) 
Conn et al. (1986) 
Cerebellum Nicoletti et al. (1986~) 
Striatum Sladeczek et al. (1 985) 
Brain slices Hunter et al. (1985) 
Brain slices Goedert et al. ( 1984) 
Neuroblastoma N IE-I15 Snider et al. (1986) 
Brain slices Downes (1983) 
B. Receptors purported to be coupled to phosphoinositide turnover" 
Substance K - 
Neurotensin - 
CCK - 
Substance P P Brain slices Watson and Downes (1983), Mantyh et al. 
Vasopressin Vl Brain slices (hippocampus) Downes (1983), Stephens and Logan ( I  986) 
(1 984) 
Superior cervical ganglion 
Neuroblastoma-glioma 
Bone et al. (1 984) 
Yano et al. (1984), Osugi et al. (1986) Bradykinin - 
TRH - GH3 pituitary cells Martin (1983), Drummond and Raeburn 
( 1984), Gershengorn and Paul (1 986) 
Anterior pituitary 
NGF - Superior cervical ganglion Lakshamanan (1978, 1979) 
Pheochromocytoma Traynor et al. (1982) 
Superior cervical ganglion Audigier et al. (1986) VIP - 
Angiotensin - Anterior pituitary Enjalbert et al. (1986) 
CCK, cholecystokinin; NGF, nerve growth factor; VIP, vasoactive intestinal peptide. 
Simmonds and Strange (1985) 
Receptors listed in the B category are those that when activated elicit a minimal increase in phosphoinositide turnover in tissue preparations 
from the CNS, even though much larger stimulations of inositol lipid turnover are, on occasion, observed in neurotumor cells or in other 
neural-related tissues. 
the magnitude of stimulated inositol lipid turnover 
(Downes, 1982, 1983). Increases in inositol lipid turn- 
over in response to cholinergic agonists is primarily, 
if not entirely, due to the activation of mAChRs. In 
those instances where a nicotinic cholinergic involve- 
ment has been implicated, e.g., superior cervical gan- 
glion (Briggs et al., 1985) or the bovine chromaffin cell 
(Eberhard and Holz, 1987), this effect may be due to 
indirect effects of the nicotinic agonist-such as the 
release of a secondary neurotransmitter or activation 
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of phospholipase C resulting from the elevation of cy- 
tosolic Ca2+ concentration. Further support for the 
sole direct involvement of mAChRs is derived from 
experiments using antagonists. Addition of musca- 
rinic antagonists such as scopolamine or atropine in- 
hibits the phosphoinositide response, whereas nico- 
tinic antagonists such as d-tubocurarine are largely 
without effect. Muscarinic agonists differ considerably 
in their ability to enhance phosphoinositide turnover 
in brain. In the cerebral cortex, a group of agonists, 
including ACh, carbamoylcholine, and oxotremo- 
rine-M, is more effective than several others, includ- 
ing pilocarpine, bethanechol, and oxotremorine 
(Fisher et al., 1983, 1984; Gonzales and Crews, 1984; 
Jacobson et al., 1985). The former group of agonists 
have been termed “group A” agonists, and the latter, 
“group B.” Not only are group B agonists less effective 
when added alone, but when present in incubations 
containing group A agonists, they block the effect of 
the more efficacious group A agonists and are, there- 
fore, considered to be partial agonists. It is of interest 
to note that this pattern of agonist efficacy is very 
different from that for another biochemical conse- 
quence of mAChR activation, inhibition of adenylate 
cyclase (Olianas et al., 1983; Brown and Brown, 
1984), but is very similar to that described for mAChR 
stimulation of guanylate cyclase (McKinney et al., 
1985). The ability of muscarinic agonists to enhance 
inositol lipid turnover is highly correlated with the 
binding characteristics of the agonist. In cerebral cor- 
tex, group A agonists readily discriminate at least two 
affinity forms (high and low) of the mAChR, whereas 
group B agonists bind predominantly to a single 
affinity form (Fisher, 1986). This observation indi- 
cates that muscarinic agonists differ in their ability to 
produce an optimal conformational change in the 
mAChR and that this is related to the subsequent acti- 
vation of the phosphodiesterase. There are also indi- 
cations that there are regional, developmental, and 
tissue differences in the way mAChRs are coupled to 
inositol lipid turnover. In the guinea pig neostriatum 
(Fisher and Bartus, 1985), in neonatal rat cerebral cor- 
tex (Heacock et al., 1987), and in the human neu- 
roblastoma SK-N-SH cell line (Fisher and Snider, 
1986), group A agonists are more potent stimulators 
of phosphoinositide hydrolysis than in the adult cor- 
tex, whereas, conversely, several group B agonists are 
more effective. 
In both the CNS and nonneural tissues, the exis- 
tence of MI and M2 mAChR subtypes has been pro- 
posed on the basis of the presumed selectivity of the 
antagonist pirenzepine (Watson et al., 1985). A sug- 
gestion that the phosphoinositide response in the CNS 
is a function of activation of the MI subtype alone ap- 
pears unwarranted (Vickroy et al., 1984); both MI 
(pirenzepine-sensitive) and M2 (pirenzepine-insensi- 
tive) characteristics are observed for stimulated lipid 
turnover. Thus, whereas pirenzepine is a potent inhib- 
itor of the phosphoinositide response in the cerebral 
cortex, hippocampus, and AtT-20/D 16-6 pituitary 
cells (Ki, - 10-20 nM) (Gonzales and Crews, 1984; 
Fisher and Bartus, 1985; Gil and Wolfe, 1985; Smith 
and Yamamura, 1985; Akiyamaet al., 1986), it iscon- 
siderably less potent in the neostriatum, astrocytoma 
cell, and brainstem (Ki, 100-300 nM) (Brown et al., 
1985; Fisher and Bartus, 1985; Lazareno et al., 1985). 
Both putative MI and M2 mAChR subtypes may be 
coupled to phosphoinositide turnover in neural tis- 
sues. 
Adrenergic. There is good evidence that the al-ad- 
renergic receptor subtype is specifically coupled to 
stimulated inositol lipid turnover. Phosphoinositide 
hydrolysis elicited by norepinephrine can be blocked 
by the a l-adrenergic blockers prazosin or phentol- 
amine, but not by yohimbine, an a2-adrenergic 
blocker, or by propranolol, a ,f3-adrenergic antagonist 
(Brown et al., 1984; Minneman and Johnson, 1984; 
Shoepp et al., 1984; Kendall et al., 1985). As is ob- 
served for the muscarinic response, adrenergic ago- 
nists differ in their ability to enhance inositol lipid 
turnover. Methoxamine and phenylephrine are par- 
tial agonists, whereas other known al-selective ago- 
nists, such as oxymetazoline, and ephedrine have no 
measurable effect (Minneman and Johnson, 1984). 
The aI-adrenergic response is detectable in most, if 
not all, brain regions, but the magnitude of the effect 
does not correlate well with the density of al-adrener- 
gic receptors, a result suggesting that receptor density 
alone is not the sole determinant of response magni- 
tude (Johnson and Minneman, 1985). An explana- 
tion may lie in the recent demonstration of a]-recep- 
tor subtypes that are differentially sensitive to the 
effect of the alkylating agent chlorethylclonidine. One 
of the a1 subtypes appears to be coupled to phospho- 
inositide turnover, whereas the other is linked to acti- 
vation of adenylate cyclase (Minneman and Johnson, 
1986). 
Histaminergic. In the CNS and neuroblastoma and 
astrocytoma cells, the phosphoinositide response ap- 
pears to be mediated through an HI receptor, because 
the stimulatory effect of histamine can be blocked by 
inclusion of pyrilamine, an HI antagonist, whereas the 
H2 antagonist cimetidine is ineffective (Subramanian 
et al., 1980). Furthermore, the magnitude of hista- 
mine-stimulated inositide turnover mirrors that of the 
density of HI receptors (Daum et al., 1983, 1984). Re- 
gional differences in coupling characteristics (ECSo 
values and partial agonist efficacies) of H1 receptors 
linked to phosphoinositide turnover have recently 
been observed (Carswell and Young, 1986). 
Serotonergic. In the cerebral cortex, 5-HT2 recep- 
tors appear to be coupled to inositide turnover, be- 
cause addition of the potent 5-HT2 antagonist ketans- 
erin blocks the response (Conn and Sanders-Bush, 
1984,1985,1986; Kendall andNahorski, 1985b). The 
situation is less clear in all other brain regions exam- 
ined, because there appears to be little correlation be- 
tween the density of [3H]ketanserin binding sites and 
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magnitude of the phosphoinositide response. Further- 
more, ketanserin does not readily antagonize the re- 
sponse in these brain regions. Recently, a new seroto- 
nin subtype, 5-HT1,, has been implicated in stimula- 
tion of phosphoinositide turnover elicited by addition 
of serotonin to the choroid plexus (Conn et al., 1986). 
This receptor subtype differs from the 5-HT2 receptor 
in its greater affinity (10-fold) for serotonin and its rel- 
ative insensitivity to ketanserin and spiperone. It 
would appear, then, that there are at least two Shy- 
droxytryptamine (5-HT) subtypes coupled to phos- 
phoinositide turnover. 
Glutarnatergic. Nicoletti et al. (1985, 1986a) have 
demonstrated that addition of glutamate or ibotenate, 
its rigid structural analog, elicits a large increase in the 
accumulation of inositol phosphates. This effect is 
most evident in neonatal tissue and declines with ma- 
turity. In hippocampus, quisqualate is a partial ago- 
nist, whereas N-methyl-D-aspartate (NMDA), kai- 
nate, quinolinate, and N-acetylaspartylglutamate are 
inactive. The pharmacological characteristics of ibo- 
tenate-stimulated phosphoinositide turnover are not 
consistent with three glutamate receptor subtypes 
characterized primarily electrophysiologically (“quis- 
qualate,” “NMDA,” or “kainate”), but rather share 
some similarities with the putative DL-2-amino-4- 
phosphonobutyric acid (APB) receptor, as deter- 
mined from recent electrophysiological and radioli- 
gand binding studies. APB antagonizes ibotenate 
stimulation of inositol lipid turnover. However, al- 
though DL-2-amino-5-phosphonovalerate (APV) 
does not antagonize ibotenate-mediated inositol lipid 
turnover, it displaces [3H]APB, an observation indi- 
cating additional complexity. Using cultured striatal 
neurons, Sladeczek et al. (1985) have also observed 
that addition of glutamate enhanced the release of 
inositol phosphate. However, the glutamate agonists’ 
profile is different from that observed in hippocam- 
pus: Whereas glutamate and quisqualate are full ago- 
nists in the striatum, NMDA and kainate are partial 
agonists. APV inhibited the reaction to NMDA, but 
not to glutamate, kainate, or quisqualate. These re- 
sults suggest that a quisqualate or NMDA receptor 
subtype is involved, although it is probable that the 
activation of several glutamate receptor subtypes can 
enhance inositol lipid turnover. As a result of these 
findings, it is now generally accepted that some gluta- 
mate receptor subtypes, long thought to couple di- 
rectly to plasma membrane ionophores, may instead 
operate through the generation of a second messenger 
signal. 
B. Receptors purported to be coupled to 
phosphoinositide turnover 
Several neuropeptide receptors may be coupled to 
inositol lipid turnover in brain, but a more definite 
statement must await independent confirmation of 
what are, at best, marginal effects on labeled inositol 
phosphate release. In this category are included sub- 
stance K, neuromedin (Hunter et al., 1985), neuro- 
tensin (Goedert et al., 1984), and cholecystokinin re- 
ceptors (Downes, 1983). The evidence suggesting a 
linkage between substance P receptors and inositol 
lipid turnover is somewhat more convincing. Mantyh 
et al. ( 1984) have demonstrated a correlation between 
the receptor density of substance P receptors, as deter- 
mined autoradiographically, and the magnitude of 
inositol phosphate release. In the hypothalamus, the 
substance P-P receptor subtype has been implicated in 
inositol lipid turnover on the basis of agonist studies 
(Watson and Downes, 1983). Addition of vasopressin 
to hippocampal slices elicits only a small increase in 
inositol phosphate release (1 50% ofcontrol) (Stephens 
and Logan, 1986), whereas its effect is much greater 
in the superior cervical ganglion (Bone et al., 1984), 
even though vasopressin may not be a natural ligand 
for this receptor (Hanley et al., 1984). In transformed 
cells of neural origin, such as neuroblastoma N1E- 
I 15, neuroblastoma-glioma hybrid, or GH3 pituitary 
cells, there is strong evidence favoring linkage of neu- 
rotensin, bradykinin, and thyrotropin-releasing hor- 
mone (TRH) receptors to stimulated inositol lipid 
turnover (Martin, 1983; Yano et al., 1984; Snider et 
al., 1986). 
C. Receptors not directly coupled to stimulated 
phosphoinositide turnover 
The list of receptors that have been studied in which 
no evidence could be found for linked phosphoinosi- 
tide turnover include several that are either positively 
or negatively coupled to adenylate cyclase, e.g., HZ- 
histaminergic, 5-HT ,-serotonergic, P-adrenergic, and 
a*-adrenergic, in addition to the nicotinic cholinergic 
and GABAergic receptors. 
D. Receptor occupancy requirements for 
phosphoinositide hydrolysis 
A close relationship exists in the CNS between oc- 
cupancy of the receptor by the agonist and the degree 
of stimulation of inositol lipid turnover. Two lines of 
evidence support this statement. First, the abilities of 
either muscarinic or adrenergic ligands to stimulate 
the release of labeled inositol phosphates correlates 
well with their abilities to displace radiolabeled antag- 
onists from specific membrane binding sites (Fisher et 
al., 1983, 1984; Minneman and Johnson, 1984). Sec- 
ond, the loss of receptor number either in vivo follow- 
ing neurotoxin treatment (Fisher et al., 1981~) or in 
vitro following irreversible inactivation of a propor- 
tion of the muscarink, a,-adrenergic, 5-HT2-seroton- 
ergic, or H,-histaminergic receptors results in a com- 
parable loss of receptor-stimulated phosphoinositide 
turnover (Johnson and Minneman, 1985; Kendall 
and Nahorski, 1985b; Kendall et al., 1985; Claro et 
al., 1986; Fisher and Snider, 1986). Some indication 
that this normal tight coupling between receptor oc- 
cupancy and response might be capable of adaptive 
change was obtained by Kendall et al. (1 985). Follow- 
ing central noradrenergic denervation, the ECso for 
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norepinephrine in the hippocampus was significantly 
reduced, and the partial agonist phenylephrine be- 
came more efficacious. Moreover, al-adrenergic re- 
ceptor alkylation with phenoxybenzamine resulted in 
a greater loss of receptor number than of the inositide 
response. These results can be interpreted as indica- 
tive of the development of a small receptor reserve for 
the phosphoinositide response following denervation. 
The observation that 1 0-fold lower concentrations of 
norepinephrine (but not of carbamoylcholine) are re- 
quired to elicit a half-maximal increase in IP3 accu- 
mulation in denervated iris smooth muscle is also 
consistent with the development of a “receptor re- 
serve” for the a,-adrenergic receptor (Akhtar and Ab- 
del-Latif, 1986). 
E. Signal transduction 
In nonneural tissues, there presently exists a sig- 
nificant amount of evidence to support the involve- 
ment of a guanine nucleotide binding (G) protein in 
the transduction process (Joseph, 1985; Litosch et al., 
1985), even though the identity of the G-proteins re- 
mains to be determined. There is little direct evidence 
to invoke such a mechanism for neural receptors at 
present. However, the inositide phosphodiesterase in 
brain has been shown to be stimulated by GTP or its 
nonhydrolyzable analogs (Gonzales and Crews, 
1985). Outside the CNS, addition of GTPyS to per- 
meabilized chromaffin cells results in a release of IP3, 
IP2, and IP, (Eberhard and Holz, 1987), whereas GTP 
potentiates the effect of TRH in cell-free preparations 
from GH3 pituitary cells (Martin et al., 1986). In hu- 
man astrocytoma cells, a strong correlation exists be- 
tween the ability of muscarinic agonists to enhance 
phosphoinositide turnover and their propensity to in- 
duce the appearance of a high-affinity GTP-sensitive 
form of the mAChR (Evans et al., 1985). These re- 
sults, taken collectively, suggest a role for G-proteins 
in signal transduction at inositide-linked receptors in 
the CNS. A recent theory proposed by Rodbell (1 985) 
envisages that, on receptor activation, the a subunit 
of the G-protein is released from the membrane and 
that subsequent modifications occur to yield new 
forms of the protein with differing functions. If cor- 
rect, the implication of this theory is that these “pro- 
grammable messengers” are, in fact, the true second 
messengers of hormone action and that IP3 and DG 
comprise tertiary signals. 
F. Desensitization 
A characteristic of stimulated inositol lipid turn- 
over is its persistence, so long as the agonist continues 
to occupy the receptor. In brain slices, for example, 
the continued release of inositol phosphates is ob- 
served for up to I20 min following addition of carba- 
moylcholine (Fisher and Bartus, 1985). Masters et al. 
( 1984) have demonstrated that in human astrocytoma 
cells, preexposure of the cells to carbamoylcholine re- 
sults in a loss of stimulated Ca2+ efflux but not of the 
production of inositol phosphates, a result suggesting 
that desensitization occurs distal to PIP2 hydrolysis. 
However, some caution is necessary before this inter- 
pretation is universally applied, because in most stud- 
ies, accumulation of IP, rather than IP3 or its isomers 
is measured. 
Modulation of phosphoinositide turnover by 
inhibitory receptors 
In addition to those receptors that can enhance the 
breakdown and resynthesis of inositol lipids, there 
may be a separate class of receptors that regulate the 
extent of stimulated inositol lipid turnover. For exam- 
ple, in the platelet, agents that elevate the tissue cyclic 
AMP concentration, such as prostaglandin E and for- 
skolin, inhibit thrombin-mediated PIP2 breakdown, 
the generation of Ca2+ signals, and subsequent physio- 
logical responses (Nishizuka, 1984). Comparable ob- 
servations in the CNS are limited and often equivocal. 
Thus, although forskolin failed to reduce either carba- 
moylcholine- or norepinephrine-mediated stimula- 
tion of inositol lipid turnover in cerebral cortex slices 
(Hollingsworth and Daly, 1985), an inhibitory effect 
was observed by Nicchitta and Williamson (1986), us- 
ing nerve ending preparations. Similarly, although it 
has been claimed that administration of excitatory 
amino acids (kainic acid, NMDA, or DL-homocys- 
teate) exerts an inhibitory effect on phosphoinositide 
turnover elicited by carbamoylcholine, histamine, or 
K+ depolarization, and not by norepinephrine 
(Baudry et al., 1986), an inhibition of norepinephrine- 
linked, and not of carbamoylcholine-linked, stimula- 
tion was observed by Nicoletti et al. (1986b). 
In the retina, light stimulation elicits an increased 
phosphoinositide turnover that is mediated in part by 
release of ACh (Anderson and Hollyfield, 198 I ; An- 
derson et al., 1983; Schmidt, 1983a,b) and can be 
blocked by administration of glycine (Anderson and 
Hollyfield, 1984). The inhibitory effect of glycine is, 
in turn, reversed by preincubation with strychnine. In 
the anterior pituitary, activation of D2-dopaminergic 
receptors results in both an inhibition of adenylate cy- 
clase and a 40% reduction in the stimulated turnover 
of inositol lipids elicited by TRH or its analog DN 
1417 (Simmonds and Strange, 1985). For the same 
tissue, Enjalbert et al. (1986) have observed that D2- 
receptor activation in lactotrophs results in a 50% in- 
hibition of angiotensin 11-stimulated inositol phos- 
phate release. To date, the D2 receptor represents the 
best-documented example of a receptor-mediated in- 
hibition of inositol phosphate release. 
Cellular and synaptic localization of receptors 
coupled to phosphoinositide turnover 
Until recently, a role for glia in stimulated phospho- 
lipid turnover in the CNS has largely been ignored, 
despite earlier indications that inositide turnover in 
both neuronal and glial cell-enriched fractions could 
be enhanced by addition of neurotransmitters (Woelk 
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et al., 1974; Abdel-Latif et al., 1974) and the fact that 
the number of glial cells may exceed that of neurons 
by severalfold in the adult mammalian CNS. The pos- 
sible involvement of glia in receptor-mediated phos- 
phoinositide turnover has been examined in primary 
cultures of cortical astrocytes judged to be at least 85% 
pure by immunocytochemical criteria (Pearce et al., 
1985). In these cultures, addition of muscarinic cho- 
linergic and al-adrenergic ligands st;mulated the re- 
lease of inositol phosphates, and in terms of agonist 
affinities and Ca2+ sensitivity, the characteristics of the 
glial response were very similar to those observed pre- 
viously for brain slices. However, using primary cul- 
tures of both neurons and glia, Gonzales et al. (1985) 
concluded that the phosphoinositide response is pri- 
marily neuronal. Nevertheless, the demonstration of 
functionally coupled muscarinic receptors on both 
neuroblastoma (Cohen et al., 1983) and astrocytoma 
(Masters et al., 1984) cells indicates that glial elements 
may also play a significant role in stimulated inositol 
lipid turnover in the CNS. 
Receptors are found at both presynaptic and post- 
synaptic sites, but most of the limited information 
presently available points to a postsynaptic localiza- 
tion for receptor-enhanced inositol lipid turnover. 
Early studies on the superior cervical ganglion indi- 
cated that much of the increased [3H]inositol incorpo- 
ration into inositol lipids that occurs after ACh addi- 
tion was localized autoradiographically to the cell 
body (Hokin, 1965). Removal of presynaptic ele- 
ments failed to reduce appreciably stimulation of lipid 
labeling elicited by addition of either ACh or nerve 
growth factor, a result indicating a postsynaptic site 
for both receptors (Hokin, 1966; Lakshamanan, 
1978, 1979). More recent studies on the hippocampus 
support this conclusion. Lesion of the adrenergic in- 
put by means of microinjection of 6-hydroxydopa- 
mine, systemic treatment with the noradrenergic 
neurotoxin DSP4, or surgical lesion of the medial 
forebrain bundle did not reduce the magnitude of al- 
adrenergic stimulated inositol phosphate release (Ja- 
nowsky et al., 1984; Kendall et al., 1985; Fowler et al., 
1986). Surgical lesion of the guinea pig fornix-fimbria 
also failed to reduce the muscarinic stimulation of 
inositol lipid turnover, even though activity of the pre- 
synaptic marker enzyme choline acetyltransferase was 
reduced by 80% (Fisher et al., 1980). In contrast, le- 
sion of postsynaptic structures with the neurotoxin 
ibotenate resulted in a substantial loss of both musca- 
rinic receptor number and stimulated PA and PI turn- 
over (Fisher et al., 198 la). Kemp and Downes (1986) 
also concluded that stimulated phosphoinositide 
turnover elicited by al-adrenergic agonists in the lat- 
eral geniculate nucleus is postsynaptic in location, be- 
cause lesion of interneurons and cell bodies of afferent 
neurons with kainic acid reduced the magnitude of 
phosphoinositide hydrolysis. 
Despite the prevailing evidence, the possibility is 
not excluded that there are also presynaptic receptors 
coupled to phosphoinositide turnover. 
POSSIBLE RELEVANCE OF 
PHOSPHOINOSITIDE TURNOVER TO 
NEURAL FUNCTION 
Neuronal plasticity 
Rapidly axonally transported proteins associated 
with neuronal growth and regeneration have been 
identified (Skene and Willard, 1981; Heacock and 
Agranoff, 1982; Benowitz and Lewis, 1983; Katz et 
al., 1985). More recently, it has been demonstrated 
that one of these proteins, designated growth-associ- 
ated protein 43 (GAP43), is characteristic of growth 
cones (Meiri et al., 1986). It is identical with the BS0 
protein found in plasma membrane (Gispen et al., 
1985) and shown to be phosphorylated by PK-C 
(Meiri et al., 1986). Because the phosphorylated form 
of BSo inhibits conversion of PIP to PIP2, this may 
constitute a regulatory mechanism (Van Dongen et 
al., 1985) of relevance to brain function. There are 
other instances of interaction between IP3 turnover 
and PK-C. For example, the 5'-phosphohydrolase in 
platelets has been postulated to be phosphorylated by 
PK-C, thus activating it (Connolly and Majerus, 
1986; Molina y Vedia and Lapetina, 1986). GAP43 
phosphorylation has also been implicated in a behav- 
ioral memory model, long-term potentiation in the 
rat hippocampus (Nelson and Routtenberg, 1985). 
A major question in understanding the biochemical 
basis of memory formation is how information ex- 
pressed in transduction processes associated with syn- 
aptic transmission can eventually lead to changes in 
macromolecular synthesis that can mediate long-term 
behavioral changes (Agranoff, 198 1). A possible 
mechanism is provided by the phosphoinositide sec- 
ond messengers, which in nonneural systems have 
been shown to lead to permanent commitment to 
growth, via oncogenes. By analogy, in neurons, a posi- 
tive feedback loop may be induced via an increased 
intracellular Ca2' content, which converts a behavior- 
ally induced transient synaptic response to a perma- 
nent one (Bemdge, 1986; Goelet et al., 1986). 
Nerve-impulse conduction: role of inositide turnover 
in diabetic neuropathy 
The known localization of PIP and PIP2 in plasma 
membranes and the propensity of these lipids to bind 
divalent cations have led to the speculation that PIP- 
PIP2 interconversions might regulate the amount of 
Ca2' bound to specific membrane sites and, thereby, 
influence the operation of Na+ and Kf channels 
(Hawthorne and Kai, 1969). However, it is unclear 
how responsive the polyphosphoinositides are to 
changes in nerve conduction, and conflicting results 
have been obtained from a variety of neural prepara- 
tions subjected to electrical stimulation (Goswami 
and Gould, 1985; for review, see Fisher and Agranoff, 
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1985). Furthermore, Mg2+, a cation present in the cy- 
tosol in much greater concentrations than Ca2+, also 
binds to the polyphosphoinositides. Indirect evidence 
for a role of the polyphosphoinositides in nerve con- 
duction has come from recent studies on sciatic 
nerves of rats made diabetic by streptozotocin, a treat- 
ment that leads to a diabetic neuropathy. Altered PI 
turnover has been previously implicated in diabetes 
(Palmano et al., 1977; Whiting et al., 1977), and re- 
cently Eichberg and colleagues (Bell et al., 1982; Berti- 
Mattera et al., 1985) have demonstrated a substantial 
increase in "Pi incorporation into PIP2 in diabetic an- 
imals. The changes could be reversed by insulin ad- 
ministration. A reduction in Na+,K+-ATPase activity 
has been observed for diabetic sciatic nerve (Greene 
and Lattimer, 1983, 1985); furthermore, the ouabain- 
sensitive component of respiration, which is reduced 
in this tissue, can be normalized by in vitro adminis- 
tration of PMA (Greene and Lattimer, 1986). Collec- 
tively, these results suggest a link among changes in 
phosphoinositide turnover, axonal conduction, and 
transmembrane ion gradients in the nerve. 
PI as an anchor for membrane proteins 
Low and colleagues have provided convincing evi- 
dence that certain membrane proteins and enzymes 
are anchored within the membrane through a cova- 
lent linkage to a ring hydroxyl of PI (Low and Finean, 
1978; Low and Zilversmit, 1980; Low et al., 1986). 
The same group has recently demonstrated that the 
attachment of Thy- 1, a cell-surface glycoprotein, to 
neural membranes also involves a PI linkage (Low 
and Kincade, 1985). A phospholipid tentatively iden- 
tified as either PIP or PIP2 is also implicated in a cova- 
lent linkage to myelin basic protein (Yang et al., 
1986). This observation assumes importance in light 
of the known high polyphosphoinositide content of 
myelin and the suggestion that this is the site of a met- 
abolically inactive pool of these lipids (Eichberg and 
Hauser, 1973). 
Cuatrecasas and colleagues have demonstrated 
that, in liver, PI may also be linked to a carbohydrate 
moiety. Following activation of phospholipase C by 
insulin, it is proposed that two second messengers are 
formed: in addition to DG, there is an inositol phos- 
phate glycan that regulates cyclic AMP phosphodies- 
terase (Saltiel and Cuatrecasas, 1986; Saltiel et al., 
1986). These findings attest further to the diversity of 
functions that inositol lipids are already known to 
play in cellular physiology. 
IS THERE A LINK BETWEEN 
PHOSPHOINOSITIDE HYDROLYSIS AND 
PSYCHIATRIC DISORDERS? 
Role of lithium 
Despite the long-term use of Lit in the treatment of 
manic depressive disorders, only recently has any hint 
of the underlying mechanism of its action become ap- 
parent. Largely as a result of the studies of Sherman 
and colleagues (Allison and Blisner, 1976; Allison et 
al., 1976; Hallcher and Sherman, 1980), it is now es- 
tablished that administration of therapeutically rele- 
vant concentrations of Li+ results in the accumulation 
of inositol monophosphate in brain and that this is the 
result of the selective inhibition of inositol 1 -phospha- 
tase (Hallcher and Sherman, 1980). The net effect of 
Li+ administration is a decrease in myo-inositol avail- 
ability, which theoretically could result in a reduction 
of PI synthesis, especially in view of the relative imper- 
meability of the blood-brain barrier to inositol (Spec- 
tor and Lorenzo, 1975). It has been proposed that Li+ 
may preferentially regulate those Ca2+-mobilizing re- 
ceptors that are "hyperactive" and thus act as a calci- 
stat (Berridge et al., 1982). Ofinterest is the recent ob- 
servation that chronic administration of Li+ results in 
an increased activity of brain inositol 1 -phosphatase, 
a mechanism presumably designed to compensate for 
the inhibitory effect of Li+ (Renshaw et al., 1986). It 
should be pointed out that the key regulated step in 
the cycle is likely to be the resynthesis of PIP2 rather 
than PI. In this context, it is noteworthy that Downes 
and Stone (1986) have observed that, in the parotid 
gland, administration of Lif resulted in an accumula- 
tion of CDP-DG (due to inositol depletion) but had 
no effect on receptor-mediated PIP2 breakdown. 
Thus, it appears that the agonist-sensitive pool of 
phosphoinositides is largely spared the effects of Li'. 
A similar conclusion was reached by Drummond and 
Raeburn ( 1984) in studies with GH3 pituitary cells. As 
in parotid gland, GH3 cells preserve their cellular lev- 
els of PIP2, even when faced with a large reduction in 
the cellular content of PI. Despite these observations, 
it remains possible that a reduction in intracellular 
inositol content could result in an adverse effect on 
the steady-state level of PIP2. Simultaneous determi- 
nation of the chemical mass of inositol, of inositol lip- 
ids, and of Li+ content in a defined cell type would do 
much to elucidate the interrelationship between Li+ 
and the phosphoinositides. A key development for fu- 
ture studies will be better separation and quantitative 
estimation of the inositol phosphates. Almost all of 
the present reports are based on 32P- or [3H]inositol- 
labeled products, which are poorly characterized and 
without chemical mass measurements. 
Receptor regulation 
In addition to providing a better insight into the 
possible physiological function of a large group of 
CNS receptors, measurement of phosphoinositide 
turnover also provides a convenient biochemical 
measure of receptor activity. This is of particular im- 
portance when one considers that many psychothera- 
peutic agents, including antidepressants and neuro- 
leptics, are known from radioligand binding assays to 
interact with more than one inositide-linked receptor. 
Inhibition by these agents of in vitro ligand binding to 
the mAChR and 5-HT2, al-adrenergic, and HI  recep- 
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tors has been documented (Peroutka and Snyder, 
1980; Richelson and Nelson, 1984a,b). Although the 
magnitude of the regulatory effects of these agents on 
receptor density following chronic administration 
may be modest, available assay techniques have 
sufficient precision to detect them. Moreover, there 
may be instances in which the changes in phosphoino- 
sitide turnover are larger than those in receptor den- 
sity, for example, as is seen in down-regulation of 5- 
HT2 receptor number and inositide stimulation fol- 
lowing iprindole treatment (Kendall and Nahorski, 
1985b). Such studies may well shed light on the long- 
term regulation of inositide second messenger genera- 
tion and on adaptive changes in chemical signaling 
within the CNS. 
CONCLUDING REMARKS 
The advantage of reviewing an active research area 
is that such a review will be timely; the disadvantage 
is that it will soon be outdated. It is our hope this re- 
view will first have served a useful function. If one 
compares the inositide-linked second messenger sys- 
tems with an earlier neurochemical era-the elucida- 
tion of cyclic AMP mechanisms-we might safely 
predict that much will be learned about the complexi- 
ties of signal transduction in the brain. Our new 
knowledge in this area should also lead to the develop- 
ment of useful pharmacological screens for the devel- 
opment of new drugs. 
It is noteworthy that our understanding of the phos- 
phoinositides began with the studies of a pioneer neu- 
rochemist, Jordi Folch-Pi, who figures centrally in re- 
cent historical reviews of the International Society for 
Neurochemistry (McIlwain, 1985) and the American 
Society for Neurochemistry (Tower, 1987). 
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